ClinicalTrials.gg
Active, not recruitingNCT07161999ALSTARSUpdated Oct 13, 2026

Study of COYA 302 for the Treatment of ALS

A Phase 2/3 interventional study of COYA 302 and Placebo in Amyotrophic Lateral Sclerosis (ALS), sponsored by Coya Therapeutics. Active, not recruiting at 25 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Coya Therapeutics · Phase 2/3, Interventional, and Treatment

How we know

Updated Oct 13, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Planned enrollment
61st of 307
120 · median 33
Started
2025
with 26 others
Phase 2/3
18 of 440
1 open now
Primary completion
2027-04
later than 44 of 128 live
Registered
399th of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 61st largest by planned enrollment of the 307 interventional ones that give a count, is one of 27 that started in 2025, is one of 18 in phase 2/3, reaches primary completion later than 44 of the 128 other live ones, and was the 399th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

The ALSTARS trial will be conducted across 20-25 sites in the US and Canada, and will evaluate the safety and efficacy of an investigational treatment called COYA 302 for adults with Amyotrophic Lateral Sclerosis (ALS).

COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. It is comprised of low dose interleukin-2 (LD IL-2) and DRL_AB (a biosimilar candidate for abatacept). Participants will be randomly assigned to receive one of 2 regimens of COYA 302 or placebo (an inactive substance) in a 1:1:1 ratio for 24 weeks in the double-blind (DB) period. Those who complete this part of the study will be eligible to receive one of the two regimens of COYA 302 for an additional 24 weeks in a blinded active extension phase (EXT). Upon completion of the EXT phase of the study, participants will be invited to participate in an open label extension (OLE).

The study will assess changes in disease progression using established ALS clinical outcome measures, including the ALS Functional Rating Scale-Revised (ALSFRS-R), neurofilament (NfL), maximal inspiratory pressure (MIP), slow vital capacity (SVC), and neurological assessments. Additional objectives include evaluation of biomarkers and safety through routine clinical assessments and adverse event monitoring.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis (ALS)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Sporadic or familial ALS, diagnosed as clinically probable, lab-supported probable, or definite ALS according to the revised El Escorial criteria
  2. Male or female participants aged 18 to 80
  3. Time since onset of ALS symptoms ≤28 months from Screening.
  4. ALSFRS-R total score ≥35 at Screening
  5. Rate of progression at baseline between -0.5 and -1.5 points per month on ALSFRS-R total score.
  6. SVC ≥60% of predicted capacity.
  7. Participants receiving riluzole must be on a stable dose for at least 30 days prior to Screening, with intent to stay on stable dosage throughout the study. If not on a stable dose of riluzole for at least 30 days prior to Screening, willing to refrain from initiation of the agent for the duration of the trial.
  8. Participants receiving edaravone (intravenous [IV] or oral, RADICAVA®) must have completed at least one treatment cycle prior to Screening, with intent to remain on stable dosage throughout the study. If participant has not completed at least one treatment cycle of edaravone at the time of Screening, willing to refrain from initiation of the agent for the duration of the trial.
  9. Participants receiving tofersen (QALSODY®) must have completed 90 days of treatment prior to Screening, with intent to remain on stable dosage throughout the study. If participant has not completed at least 90 days of tofersen at the time of Screening, willing to refrain from initiation of the agent for the duration of the trial.

Key Exclusion Criteria:

  1. Any and/or unstable medical (including active systemic infections requiring treatment), surgical, or psychiatric condition or laboratory abnormality other than ALS, in the judgement of the Investigator.
  2. Active suicidality (e.g., any suicide attempts within the past 12 months or any current suicidal intent, including a plan, as assessed by the C-SSRS, score of "YES" on questions 4 or 5; and/or based on clinical evaluation by the Investigator).
  3. (ALT) or aspartate aminotransferase (AST) levels greater than 3 times the (ULN).
  4. Significant renal impairment as determined by estimated (eGFR) of \<60 mL/min.
  5. Pre-existing or significant pulmonary impairment including those with an ≤ 2 liters or \< 75% predicted for height and age, in the judgement of the Investigator.
  6. Clinically significant history of cardiac function impairment including cardiac below 40%, ventricular wall motion abnormalities, or coronary artery disease.
  7. Any organ allografts.
  8. A positive tuberculosis (TB) test indicating a latent TB infection or a positive test for viral hepatitis.
  9. Currently receiving or have received abatacept treatment within 75 days prior to Screening.
  10. Currently receiving or have received interleukin-2 (IL-2) treatment within 30 days prior to Screening.
  11. Currently receiving or expected to receive therapy (e.g., cyclosporine, sirolimus, tacrolimus, mycophenolate mofetil, systemic ) over the course of the study.
  12. Planning to receive a during the study or within 3 months of discontinuation.
  13. Current participation in another interventional clinical trial and/or participation in any medication or device clinical trial within 30 days prior to Screening or 5 half-lives of elimination of the investigational medication, whichever is longer.
  14. Previous participation in any COYA 302 (LD rhIL-2 and DRL_AB) study.
  15. Uncontrolled condition.
  16. Presence of an indwelling central catheter.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    DB: COYA 302 Regimen 1

    Regimen 1: 125 mg DRL\_AB and Placebo LD rhIL-2 on Week 1, and LD rhIL-2 (0.10 mg \[1M IU\]) and Placebo DRL\_AB on Week 3 administered via subcutaneous (SC) injection for 5 consecutive days every other week. This dosing regimen will be repeated until completing 6 (six) 4-week cycles, for a total of 24 weeks.

    Drug: COYA 302 · Drug: Placebo

  • Experimental
    DB: COYA 302 Regimen 2

    Regimen 2: 0.10 mg (1M IU) LD rhIL-2 and 125 mg DRL\_AB on both Weeks 1 and 3 administered via SC injection for 5 consecutive days every other week. This dosing regimen will be repeated until completing 6 (six) 4-week cycles, for a total of 24 weeks.

    Drug: COYA 302

  • Placebo comparator
    DB: Placebo

    Placebo LD IL-2 and Placebo DRL\_AB (Weeks 1 and 3) administered via SC injection for 5 consecutive days every other week. This dosing regimen will be repeated until completing 6 (six) 4-week cycles, for a total of 24 weeks.

    Drug: Placebo

  • Experimental
    EXT: Regimen 1

    Regimen 1: 125 mg DRL\_AB and Placebo LD rhIL-2 on Week 1, and LD rhIL-2 (0.10 mg \[1M IU\]) and Placebo DRL\_AB on Week 3 administered via SC injection for 5 consecutive days every other week. This dosing regimen will be repeated until completing 6 (six) 4-week cycles, for a total of 24 weeks.

    Drug: COYA 302

  • Experimental
    EXT: Regimen 2

    Regimen 2: 0.10 mg (1M IU) LD rhIL-2 and 125 mg DRL\_AB on both Weeks 1 and 3 administered via SC injection for 5 consecutive days every other week. This dosing regimen will be repeated until completing 6 (six) 4-week cycles, for a total of 24 weeks.

    Drug: COYA 302

Interventions

  • DrugCOYA 302

    Administered as specified in the treatment arm.

    Also known as: LD rhIL-2 and CTLA-4 Ig

  • DrugPlacebo

    Administered as specified in the treatment arm.

06

What researchers measure

Primary outcomes

  1. The change in disease progression as measured by the Revised ALS Functional Rating Scale (ALSFRS-R)

    The ALSFRS-R is an ordinal rating scale used to determine a participant's subjective assessment of their capability and independence with 12 functional activities. The maximal score is 48.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Serum neurofilament light chain (NfL)

    Serum NfL will be quantified as a biomarker of neuroaxonal injury.

    Time frame: Baseline to Week 24

  2. Maximal Inspiratory Pressure (MIP)

    MIP is a measure of respiratory muscle strength and will be evaluated as an indicator of pulmonary function decline.

    Time frame: Baseline to Week 24

  3. Combined Assessment of Function and Survival (CAFS)

    CAFS is a ranked analysis combining functional decline (ALSFRS-R change) and survival status to provide a composite efficacy endpoint.

    Time frame: Baseline to Week 24

  4. Slow Vital Capacity (SVC)

    SVC is a measure of respiratory function.

    Time frame: Baseline to Week 24

07

Study locations

25 sites
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Apr 2027, 18 months after the start.

Of 22 phase 2/3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 109. This study's planned 18 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jan 2027 → Apr 2027 and completion Jul 2027 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2025
First posted
Sep 9, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Apr 2027was Jan 2027
CompletionEst.
Oct 2027was Jul 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 13, 2026
Primary completion
Jan 2027→Apr 2027
Oct 13, 2026
Study completion
Jul 2027→Oct 2027
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Active, not recruiting
    Primary completion Jan 2027→Apr 2027
    Study completion Jul 2027→Oct 2027
    + 6 other changes: identifiers, verification date, description, arm descriptions, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07161999
Lead sponsor
Coya Therapeutics
Responsible party
Sponsor
First posted
Sep 9, 2025
Start date
Oct 1, 2025
Primary completion
Apr 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion